切换至 "中华医学电子期刊资源库"
高级检索
中华临床医师杂志(电子版)

中华临床医师杂志(电子版) ›› 2018, Vol. 12 ›› Issue (03) : 168 -172. doi: 10.3877/cma.j.issn.1674-0785.2018.03.010

所属专题： 文献；

综述

卵巢癌腹水非细胞成分对肿瘤的影响
王霞1, 郝晓莹1,†(), 赵卫红1, 郝敏1   
  1. 1. 030001　太原，山西医科大学第二医院妇产科
  • 收稿日期:2017-09-04 出版日期:2018-02-01
  • 通信作者: 郝晓莹

Effect of acellular fraction of ovarian cancer ascites on tumor

Xia Wang1, Xiaoying Hao1,†(), Weihong Zhao1, Min Hao1   

  1. 1. Department of Gynecology and Obstetrics, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China
  • Received:2017-09-04 Published:2018-02-01
  • Corresponding author: Xiaoying Hao
  • About author:
    Corresponding author: Hao Xiaoying, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

王霞, 郝晓莹, 赵卫红, 郝敏. 卵巢癌腹水非细胞成分对肿瘤的影响[J]. 中华临床医师杂志(电子版), 2018, 12(03): 168-172.

Xia Wang, Xiaoying Hao, Weihong Zhao, Min Hao. Effect of acellular fraction of ovarian cancer ascites on tumor[J]. Chinese Journal of Clinicians(Electronic Edition), 2018, 12(03): 168-172.

卵巢癌病死率居妇科肿瘤最高，早期诊断率低，多数初次诊断时即为晚期。超过1/3的卵巢癌以及几乎全部的复发患者伴有腹水的产生。卵巢癌腹水中非细胞成分丰富复杂，包括细胞因子、蛋白质、代谢物和外泌体，形成复杂的腹水肿瘤微环境，影响肿瘤细胞的生物学行为及疾病进展。现就卵巢癌腹水非产细胞成分的种类、对肿瘤细胞及疾病的影响作一概述。

关键词: 卵巢癌, 腹水, 非细胞成分

Ovarian cancer has the highest mortality among gynecologic cancers. The rate of early diagnosis is low and most cases have reached an advanced stage at the initial diagnosis. More than one-third of ovarian cancer patients present a large amount of ascites at the time of diagnosis. Acellular fraction of ovarian cancer ascites richly includes cytokines, proteins, metabolites, and exosomes, constitutes a unique and complicated tumor microenvironment, and influences the biological behavior of tumor cells and the progression of the disease. This paper gives an overview of the acellular fraction of ovarian cancer ascites and its effect on tumor.

Key words: Ovarian cancer, Ascites, Acellular fraction
[1]
Lengyel E. Ovarian cancer development and metastasis [J]. Am J Pathol, 2010, 177(3): 1053-1064.
[2]
Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research [J]. Nat Rev Cancer, 2013, 13(4): 273-282.
[3]
张菲菲，金世柱，刘自帅. 恶性腹水的治疗新观点 [J]. 胃肠病学和肝病学杂志, 2017, 26(4): 476-478.
[4]
Kim S, Kim B, Song Y. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer [J]. Cancer Sci, 2016, 107(9): 1173-1178.
[5]
Matte I, Lane D, Laplante C. Profiling of cytokines in human epithelial ovarian cancer ascites [J]. Am J Cancer Res, 2012, 2(5): 566-580.
[6]
So KA, Min KJ, Hong JH. Interleukin-6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelial-mesenchymal transition [J]. Int J Oncol, 2015, 47(4): 1451-1459.
[7]
Kim S, Gwak H, Kim HS. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro [J]. Oncotarget, 2016, 7(50): 83148-83159.
[8]
Yin J, Zeng F, Wu N. Interleukin-8 promotes human ovarian cancer cell migration by epithelial-mesenchymal transition induction in vitro [J]. Clin Transl Oncol, 2015, 17(5): 365-370.
[9]
Wang Y, Xu RC, Zhang XL. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion [J]. Cytokine, 2012, 59(1): 145-155.
[10]
Matte I, Lane D, Bachvarov D. Role of malignant ascites on human mesothelial cells and their gene expression profiles [J]. BMC Cancer, 2014, 14: 288.
[11]
Lane D, Matte I, Rancourt C. Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis [J]. J Ovarian Res, 2012, 5(1): 34.
[12]
Lane D, Matte I, Laplante C. CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling [J]. Mol Cancer, 2016, 15(1): 58.
[13]
Biskup K, Braicu EI, Sehouli J. The ascites N-glycome of epithelial ovarian cancer patients [J]. J Proteomics, 2017, 157: 33-39.
[14]
Yunusova NV, Villert AB, Spirina LV. Insulin-Like Growth Factors and Their Binding Proteins in Tumors and Ascites of Ovarian Cancer Patients: Association With Response To Neoadjuvant Chemotherapy [J]. Asian Pac J Cancer Prev, 2016, 17(12): 5315-5320.
[15]
Saltzman AK, Hartenbach EM, Carter JR. Transforming growth factor-alpha levels in the serum and ascites of patients with advanced epithelial ovarian cancer [J]. Gynecol Obstet Invest, 1999, 47(3): 200-204.
[16]
Abendstein B, Stadlmann S, Knabbe C. Regulation of transforming growth factor-beta secretion by human peritoneal mesothelial and ovarian carcinoma cells [J]. Cytokine, 2000, 12(7): 1115-1119.
[17]
Shender VO, Pavlyukov MS, Ziganshin RH. Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication [J]. Mol Cell Proteomics, 2014, 13(12): 3558-3571.
[18]
Senger DR, Galli SJ, Dvorak AM. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid [J]. Science, 1983, 219(4587): 983-985.
[19]
杨娜，陈琦. 血管内皮生长因子及其受体与卵巢癌相关性的研究进展 [J]. 中国老年学杂志, 2017, 37(2): 491-494.
[20]
Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research [J]. Front Oncol, 2013, 3: 256.
[21]
苏杭，胡冰. 恶性腹腔积液的靶向治疗进展 [J]. 医药导报, 2016, 35(5): 496-500.
[22]
Byrne AT, Ross L, Holash J. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model [J]. Clin Cancer Res, 2003, 9(15): 5721-5728.
[23]
Yukita A, Asano M, Okamoto T. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo [J]. Anticancer Res, 2000, 20(1a): 155-160.
[24]
Bamias A, Koutsoukou V, Terpos E. Correlation of NK T-like CD3＋CD56＋ cells and CD4＋CD25＋(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy [J]. Gynecol Oncol, 2008, 108(2): 421-427.
[25]
Santin AD, Hermonat PL, Ravaggi A. Secretion of vascular endothelial growth factor in ovarian cancer [J]. Eur J Gynaecol Oncol, 1999, 20(3): 177-181.
[26]
夏红慧，詹娜. 卵巢癌腹水中血管内皮生长因子的表达及临床意义 [J]. 中国生育健康杂志, 2016, 27(2): 127-129.
[27]
Zhan N, Dong WG, Wang J. The clinical significance of vascular endothelial growth factor in malignant ascites [J]. Tumour Biol, 2016, 37(3): 3719-3725.
[28]
张庆松，李燕华. 贝伐单抗在卵巢癌中的应用进展 [J]. 肿瘤学杂志, 2016, 22(4): 310-315.
[29]
Hamilton CA, Maxwell GL, Chernofsky MR. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer [J]. Gynecol Oncol, 2008, 111(3): 530-532.
[30]
Belotti D, Paganoni P, Manenti L. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation [J]. Cancer Res, 2003, 63(17): 5224-5229.
[31]
毛柳. 卵巢癌腹水及外周血CD4~＋CD25~＋Treg/CD4~＋T细胞含量及其意义分析 [J]. 中国妇幼保健, 2016, 31(22): 4871-4874.
[32]
Zhang Y, Chen Q. Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer [J]. Braz J Med Biol Res, 2017, 50(6): e6104.
[33]
Jesionowska A, Cecerska-Heryc E, Matoszka N. Lysophosphatidic acid signaling in ovarian cancer [J]. J Recept Signal Transduct Res, 2015, 35(6): 578-584.
[34]
Li H, Wang D, Zhang H. Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice [J]. Mol Cancer Ther, 2009, 8(6): 1692-1701.
[35]
唐慧，伍海姗，杨怡. 外泌体源性microRNA在疾病诊疗中的研究进展 [J]. 中南大学学报(医学版), 2015, 40(11): 1270-1275.
[36]
邹玉鹏，李力. 卵巢癌血清新型肿瘤标志物研究与应用现况 [J]. 肿瘤防治研究, 2017, 44(9): 631-635.
[37]
Barni S, Cabiddu M, Ghilardi M. A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites [J]. Crit Rev Oncol Hematol, 2011, 79(2): 144-153.
[38]
李岩，胡冰. 恶性腹水的抗血管生成治疗进展 [J]. 安徽医药, 2013, 17(4): 541-543.
[39]
Puiffe ML, Le PC, Filali-Mouhim A. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer [J]. Neoplasia, 2007, 9(10): 820-829.
[40]
Meunier L, Puiffe ML, Le PC. Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model [J]. Transl Oncol, 2010, 3(4): 230-238.
[41]
Cohen M, Pierredon S, Wuillemin C. Acellular fraction of ovarian cancer ascites induce apoptosis by activating JNK and inducing BRCA1, Fas and FasL expression in ovarian cancer cells [J]. Oncoscience, 2014, 1(4): 262-271.
[42]
Lane D, Goncharenko-Khaider N, Rancourt C. Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation [J]. Oncogene, 2010, 29(24): 3519-3531.
[43]
Lane D, Matte I, Rancourt C. The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer [J]. J Ovarian Res, 2010, 3: 1.
[44]
Lane D, Robert V, Grondin R. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells [J]. Int J Cancer, 2007, 121(6): 1227-1237.
[45]
Ueda T, Maehara M, Takahashi Y. Clinical significance of cell-free and concentrated ascites re-infusion therapy for advanced and recurrent gynecological cancer [J]. Anticancer Res, 2012, 32(6): 2353-2357.
[46]
曾凡清，吴南顺，殷娟. 紫杉醇联合卡铂不同给药途径治疗卵巢癌的疗效观察 [J]. 中国药业, 2015, 24(23): 171-172.
[47]
吴国芳，刘丽. 顺铂不同给药途径联合紫杉醇静脉滴注治疗晚期卵巢癌的疗效和不良反应 [J]. 中国肿瘤临床与康复, 2016, 23(3): 300-302.
[48]
Nicoletto MO, Casarin A, Baldoni A. Intraperitoneal chemotherapy in patients pretreated for ovarian cancer matched with patients treated with parenteral chemotherapy [J]. Anticancer Res, 2016, 36(12): 6541-6546.
[1] 许彩, 周苑, 赵胜, 崔新伍. 卵巢-附件报告与数据系统在超声诊断卵巢-附件肿块良恶性中的价值[J]. 中华医学超声杂志（电子版）, 2023, 20(01): 51-56.
[2] 刘真真, 石志敏, 徐钟慧, 李建初, 姜玉新. IOTA ADNEX模型与简单法则对附件区疑难病变的诊断价值[J]. 中华医学超声杂志（电子版）, 2020, 17(11): 1084-1089.
[3] 刘德林, 黄斌, 孙希希, 孔梓祥. 人工腹水辅助超声引导下经皮微波消融治疗邻近横膈肝癌的应用价值[J]. 中华医学超声杂志（电子版）, 2020, 17(08): 776-781.
[4] 陈荟竹, 郭应坤, 汪昕蓉, 宁刚, 陈锡建. 上皮性卵巢癌"二元论模型"的分子生物学研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 394-402.
[5] 潘凌亚. CA125在卵巢管理中的应用[J]. 中华妇幼临床医学杂志(电子版), 2021, 17(06): 746-746.
[6] 张晓贝, 曹栋, 杨宝顺, 俞永江. 肝硬化腹水合并腹股沟疝的临床治疗进展[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(02): 121-124.
[7] 王慧, 贾艳慧, 冯翔. 不同手术方式在腹股沟疝合并肝硬化腹水患者中的临床疗效[J]. 中华疝和腹壁外科杂志(电子版), 2021, 15(06): 595-598.
[8] 武雅雯, 叶明侠, 李立安, 王铭洋, 孟元光. 机器人、腹腔镜与开腹手术治疗中晚期卵巢癌的临床分析[J]. 中华腔镜外科杂志(电子版), 2022, 15(06): 352-356.
[9] 赵仁峰. 经脐单孔微小腹腔镜在诊治晚期卵巢癌的应用[J]. 中华腔镜外科杂志(电子版), 2020, 13(05): 0-0.
[10] 莫婧, 陈国伟, 张世玉. 术后不同时间腹腔热灌注化疗对卵巢癌患者肿瘤标志物水平的影响[J]. 中华临床医师杂志(电子版), 2023, 17(02): 165-170.
[11] 黄晴, 赵瑞珩, 钱惠英. PCI-24781诱导SKOV-3细胞凋亡及相关机制的研究[J]. 中华临床医师杂志(电子版), 2022, 16(08): 775-781.
[12] 谢文强, 张强, 陈文, 李长科, 魏兵华, 唐盈. 实施加速康复外科管理对卵巢癌分期手术老年患者术后早期恢复的影响[J]. 中华临床医师杂志(电子版), 2021, 15(12): 999-1002.
[13] 黄世明, 吴思雨, 孙永锋, 尹亮, 岳建兰, 林志春. 不同影像诊断方法对卵巢癌腹膜转移诊断价值的系统评价[J]. 中华介入放射学电子杂志, 2021, 09(02): 177-182.
[14] 李京菊, 刘德良, 谭玉勇. 卵巢癌结构域蛋白酶-6A在胃腺癌中的表达及临床意义[J]. 中华胃肠内镜电子杂志, 2022, 09(01): 36-40.
[15] 卜智斌, 叶萌, 洪丽杰, 姜鹏涛, 莫自楷. 超声介导的载药微泡对裸鼠卵巢癌皮下移植瘤的抑制作用[J]. 中华老年病研究电子杂志, 2021, 08(01): 20-24.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号